arrow_back Trending Legislation
Share share

Increased Transparency in Foreign Drug Manufacturing: Safer Medicines for USA

This act aims to enhance the safety of medicines available in the USA by improving oversight of foreign manufacturers. It means that companies producing drug ingredients abroad will need to report their data more frequently, helping to detect issues faster and ensuring the medicines you take are safe and effective.
Key points
Foreign manufacturers of drug ingredients will be required to report information about their facilities and products more frequently.
Pharmaceutical companies must confirm they know all drug manufacturing locations and inform foreign suppliers of their obligations.
Reports on drug production amounts will be submitted quarterly instead of annually, improving market oversight.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Improved Transparency of Foreign Drug Manufacturing Act of 2022
Print number: HR 6483
Sponsor: Rep. Eshoo, Anna G. [D-CA-18]
Process start date: 2022-01-25
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Increased Transparency in Foreign Drug Manufacturing: Safer Medicines for USA

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 6483.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-01-25.

What are the main provisions?

Key points include:

  • Foreign manufacturers of drug ingredients will be required to report information about their facilities and products more frequently.
  • Pharmaceutical companies must confirm they know all drug manufacturing locations and inform foreign suppliers of their obligations.
  • Reports on drug production amounts will be submitted quarterly instead of annually, improving market oversight.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Eshoo, Anna G. [D-CA-18].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Analysis and Potential Impact of HR 6483

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health